olaparib
AstraZeneca Optimistic About Phase III Camizestrant Data in 2025, Reports Strong Q4 Product Growth
Premium
If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.
Repare Therapeutics Shuffles Pipeline, Pauses Some Programs Pending Partnership
The firm will pause development of lunresertib and camonsertib while focusing on development of two newer programs.
Researchers Aim to Confirm Benefits of Non-Hormonal Therapy for Certain Prostate Cancer Patients
Premium
Prostate cancer patients with BRCA2 and other homologous recombination repair mutations fared better on Lynparza than those without genomic alterations.
European Commission Approves AstraZeneca's Imfinzi Regimens Based on MMR Status
Depending on MMR status, endometrial cancer patients can receive first-line therapy with Imfinzi and chemo followed by Imfinzi alone or Imfinzi with Lynparza.
Io9 AI-Driven Digital Pathology Test Shows Potential to Inform Breast, Ovarian Cancer Therapy
Premium
The firm hopes to develop its DeepHRD digital pathology test as an alternative to costly companion diagnostics based on next-generation sequencing.